Meeting
2012 Breast Cancer Symposium
Early efficacy analysis of the AE37 vaccine in patients with HER2 low-expressing and triple-negative breast cancer.
Authors
Elizabeth Mittendorf
University of Texas M. D. Anderson Cancer Center
Elizabeth Mittendorf , Sonia Perez , Diane Hale , Timothy Vreeland , Alan Sears , Guy Clifton , Alexandros Ardavanis , Nathan Shumway , James Murray , Sathibalan Ponniah , Michael Papamichail , George Peoples
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Poster Discussion Session B
Track
Survivorship and Health Policy,Systemic Therapy
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT00524277
Citation
J Clin Oncol 30, 2012 (suppl 27; abstr 109)
DOI
10.1200/jco.2012.30.27_suppl.109
Abstract #
109
Poster Bd #
B9
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting.
First Author: Kaitlin M. Peace
Poster
2014 ASCO Annual Meeting
Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.
First Author: Elizabeth Ann Mittendorf
Poster
2019 ASCO Annual Meeting
Immunologic responses in triple-negative breast cancer patients in a randomized phase IIb trial of nelipepimut-S plus trastuzumab versus trastuzumab alone to prevent recurrence.
First Author: Jessica Campf
Poster
2015 ASCO Annual Meeting
Final pre-specified analysis of the phase II trial of the AE37+GM-CSF vaccine in high risk breast cancer patients to prevent recurrence.
First Author: Julia M. Greene